Ginkgo Bioworks Holdings (DNA) Earnings Analysis
Ginkgo Bioworks Holdings (DNA) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -1.39 USD vs -1.21115 USD est (-14.8%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -1.46.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does DNA next report earnings?
No confirmed upcoming earnings date is currently scheduled for DNA. This page updates as the calendar is published.
DNA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -1.39 USD | -1.21115 USD | -14.8% | Miss |
| 2026-02-26 | -1.42 USD | -1.8 USD | +21.1% | Beat |
| 2025-11-06 | -1.45 USD | -1.24 USD | -16.9% | Miss |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
DNA valuation and analyst view
| Trailing P/E | -1.46 |
|---|---|
| Trailing EPS | -5.1104 USD |
| Price / book | 1.05 |
| Dividend yield | 0.00% |
| Market cap | 0.52B |
| Analyst consensus | Buy (5 buy / 2 hold / 4 sell) |
| Avg price target | 9 USD |
Related research pages
Frequently asked questions
When is Ginkgo Bioworks Holdings (DNA)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for DNA. This page updates as the calendar is published.
Did DNA beat earnings last quarter?
In its 2026-05-07 report, DNA posted EPS of -1.39 USD versus a -1.21115 USD estimate — a miss of 14.8%.
What is DNA's earnings track record?
Over the last 3 reported quarters with consensus data, DNA beat estimates 1 times (33%).
What is DNA's current P/E ratio and EPS?
DNA trades at a trailing P/E of -1.46 on trailing EPS of -5.110398735439352 USD.
What do analysts rate DNA?
Analyst consensus is "Buy" across 11 ratings (0 strong buy, 5 buy, 2 hold, 4 sell, 0 strong sell). Average 12-month price target: 9 USD.